1. T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
- Author
-
Xuexian O. Yang, Yeonseok Chung, Tomohide Yamazaki, Natalia Martin-Orozco, Sijie Lu, Patrick Hwu, Pawel Muranski, Nicholas P. Restifo, Willem W. Overwijk, and Chen Dong
- Subjects
Lung Neoplasms ,T cell ,Immunology ,chemical and pharmacologic phenomena ,Lymphocyte Activation ,Interleukin 21 ,Mice ,Cell Line, Tumor ,medicine ,Cytotoxic T cell ,Animals ,Immunology and Allergy ,Antigen-presenting cell ,Melanoma ,Mice, Knockout ,CD40 ,biology ,Interleukin-17 ,hemic and immune systems ,Dendritic cell ,T-Lymphocytes, Helper-Inducer ,Natural killer T cell ,medicine.anatomical_structure ,Infectious Diseases ,CELLIMMUNO ,biology.protein ,Interleukin 12 ,Cancer research ,T-Lymphocytes, Cytotoxic - Abstract
Although T helper 17 (Th17) cells have been found in tumor tissues, their function in cancer immunity is unclear. We found that interleukin-17A (IL-17A)-deficient mice were more susceptible to developing lung melanoma. Conversely, adoptive T cell therapy with tumor-specific Th17 cells prevented tumor development. Importantly, the Th17 cells retained their cytokine signature and exhibited stronger therapeutic efficacy than Th1 cells. Unexpectedly, therapy using Th17 cells elicited a remarkable activation of tumor-specific CD8(+) T cells, which were necessary for the antitumor effect. Th17 cells promoted dendritic cell recruitment into the tumor tissues and in draining lymph nodes increased CD8 alpha(+) dendritic cells containing tumor material. Moreover, Th17 cells promoted CCL20 chemokine production by tumor tissues, and tumor-bearing CCR6-deficient mice did not respond to Th17 cell therapy. Thus, Th17 cells elicited a protective inflammation that promotes the activation of tumor-specific CD8(+) T cells. These findings have important implications in antitumor immunotherapies.
- Published
- 2009
- Full Text
- View/download PDF